CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Chief Medical Officer sold 4,087 shares at an average $28.52 ($116,568)
- 4 Open-market sale Director sold 2,970 shares at $28.44 ($84,467)
- 4 Open-market sale COFO and Secretary sold 2,636 shares at $28.44 ($74,968)
- 4 Open-market sale President and CEO sold 4,800 shares at $28.44 ($136,512)
- 4/A Open-market sale COFO and Secretary sold 2,912 shares at $28.70 ($83,574)
- 4 Open-market sale Chief Medical Officer sold 2,913 shares at $28.69 ($83,574)
- 4 Open-market sale COFO and Secretary sold 2,912 shares at $28.70 ($83,574)
- 4 Open-market sale President and CEO sold 5,029 shares at $28.73 ($144,483)
- 4 Open-market sale Director sold 20,000 shares at $30.48 ($609,600)
- 4 Open-market sale Director sold 20,000 shares at an average $30.27 ($605,463)
- 4 Option exercise COFO and Secretary acquired 20,000 shares (option exercise)
- 4 Open-market sale Director sold 20,000 shares at an average $30.82 ($616,304)
- 4 Open-market sale Director sold 20,000 shares at an average $31.61 ($632,282)
- 4 Open-market sale Chief Medical Officer sold 2,424 shares at $31.98 ($77,520)
- 4 Open-market sale President and CEO sold 2,404 shares at $33.22 ($79,861)
- 4 Open-market sale Director sold 2,253 shares at $33.22 ($74,845)
- 4 Open-market sale COFO and Secretary sold 2,576 shares at $33.22 ($85,575)
- 4 Open-market sale Chief Medical Officer sold 2,576 shares at $33.22 ($85,575)
- 4 Grant or award Chief Medical Officer acquired 22,500 shares (grant or award)
- 4 Grant or award COFO and Secretary acquired 22,500 shares (grant or award)
Page 8 of 22 · 436 filings